Sio Gene Therapies Inc. (SIOX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New York City, NY, United States. The current CEO is David W. Nassif.
SIOX has IPO date of 2015-06-11, 12 full-time employees, listed on the NASDAQ Global Select.
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
